Valuation Trading Multiples & Precedent Transactions: Cell and Gene Therapy Biopharma Companies
Valuation benchmarks for Cell and Gene Therapy Biopharma Companies. Access public trading comps, EV/EBITDA acquisition multiples, and private market data for pitch books and valuation analysis.
1.1 - Cell and Gene Therapy Biopharma Companies Market Context & Valuation Drivers
Public biopharmaceutical companies focused on cell and gene therapy discover, develop, manufacture, and commercialize advanced therapeutics targeting oncology, virology, immunology, and rare genetic diseases. They monetize through prescription drug sales, royalties, and partnering deals, supported by global regulatory approvals and market access. These companies are comparable for valuation because they share R&D‑intensive pipelines, specialized GMP manufacturing, significant launch-driven revenue profiles, and exposure to similar reimbursement and commercial execution dynamics.
Typical capabilities include discovery platforms for genetic targets, clinical development across Phase I–IV, and regulatory strategy for accelerated pathways. They operate GMP facilities for viral vector production and cell processing, manage complex autologous and allogeneic supply chains, and run global commercialization, market access, and medical affairs. Portfolios span oncology cell therapies, gene therapies for rare diseases, HIV and hepatitis antivirals, immunology drugs, and precision medicines for inherited conditions.
Primary customers and channels include hospitals and specialty clinics, payers and pharmacy benefit managers, and government health programs across oncology, virology, and rare disease care. Key valuation benchmarks include product revenue growth, launch ramp and patient penetration, gross margin and COGS for CGT manufacturing, durability of response and reimbursement, and pipeline productivity measured by clinical success rates and near-term regulatory catalysts.
2. Valuation Analysis: Public Trading Comps & Multiples for Cell and Gene Therapy Biopharma Companies companies
2.1 - Public Peer Groups & Median Valuation Multiples for Cell and Gene Therapy Biopharma Companies sector
Comparable group 1: Cell and Gene Therapy Biopharma Companies
Novartis
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of innovative medicines and treatments, focusing on the research, development, manufacturing, and marketing of patented pharmaceuticals in areas such as oncology, immunology, cardiovascular, ophthalmology, and neuroscience to improve and extend lives worldwide.
- Key Products:
- Oncology Treatments: Medications for various types of cancer
- Immunology Drugs: Treatments for autoimmune and inflammatory diseases
- Cardiovascular Medicines: Drugs for heart and vascular conditions
- Neuroscience Therapies: Pharmaceuticals for neurological and psychiatric disorders
- Ophthalmology Solutions: Treatments for eye diseases and conditions
Gilead Sciences
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of innovative biopharmaceuticals that treat and prevent severe diseases including HIV/AIDS, liver diseases, cancer, and inflammation through research-based development, ensuring global health advancement with a diverse pipeline of therapeutics and extensive scientific innovation.
- Key Products:
- HIV Treatments: Comprehensive range of antiretroviral medications for managing and preventing HIV
- Oncology Solutions: Therapeutics targeting various cancers and cell therapies
- Liver Disease Treatments: Medicines for hepatitis B, hepatitis C, and other liver conditions
- Virology Solutions: Broad pharmaceutical range for treating viral infections
- Inflammation Treatments: Drugs addressing inflammatory diseases and conditions.